Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Alteryx Therapeutics Ltd in metadata) covers the quarter ended June 30, 2009, and the 12-month period ending on the same date. The registrant is an Australian entity admitted on the basis of commitments, reporting in Australian Dollars (A$).
Key Financial Metrics
| Metric | Current Quarter (A$'000) | Year to Date (A$'000) |
|---|---|---|
| Receipts from Customers | 0 | 0 |
| Net Operating Cash Flows | (1,477) | (7,008) |
| Net Investing Cash Flows | 0 | (25) |
| Net Financing Cash Flows | 0 | 102 |
| Net Decrease in Cash | (1,477) | (6,931) |
| Cash at End of Period | 4,305 | 4,305 |
| Staff Costs Paid | (337) | (1,527) |
| R&D Costs Paid | (662) | (4,055) |
The filing does not provide a clear value for revenue, profit, margins, or debt levels, as the report focuses exclusively on cash flow activities. No borrowings or repayments were recorded during the period.
Material Changes and Activities
- Operating Burn: The company continued to burn cash, with operating outflows of A$1.5 million for the quarter and A$7.0 million for the year. Research and development represented the largest cash outflow category.
- Financing Activity: During the 12-month period, the company raised A$114,000 from share issues but incurred A$12,000 in capital raising costs.
- Non-Cash Transactions: The company issued 1,099,818 options to consultants and employees in lieu of cash services during the period.
- Related Party Payments: A$61,000 was paid to directors and associates during the quarter for salaries, fees, and consulting at normal commercial rates.
Guidance, Risks, and Unusual Items
The filing contains no management commentary, forward-looking guidance, or specific risk disclosures beyond the standard compliance statement. The company reported no acquisitions or disposals of business entities. A notable item was a GST refund repayment of A$309,000 recorded in the year-to-date operating cash flows.
Investor Verification Checklist
- Verify the company's current cash runway given the A$4.3 million cash balance and A$7 million annual operating burn rate.
- Confirm the status of the 1,099,818 options issued to employees and consultants and their potential dilution impact.
- Investigate the lack of revenue receipts and the timeline for potential commercialization or funding events.
- Review the specific nature of the "Foreign Currency bond refund" of A$11,000 included in investing activities.